AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
CSPC will receive an upfront payment of $100 million from AstraZeneca
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Subscribe To Our Newsletter & Stay Updated